MGIM
SUPN icon

M&G Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

M&G Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-90,855
Closed -$2.18M – 447
2019
Q4 		$2.18M Buy
+90,855
New +$2.21M 0.02% 266

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

M&G Investment Management's SUPN Position: Q1 2020 in Review

M&G Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2020, closing a stake of 90,855 shares — an estimated $2.18M sold.

M&G Investment Management first reported a position in SUPN in Q4 2019 and held it in 1 quarter. The position peaked at $2.18M in Q4 2019. 208 funds tracked by Wall St. Rank hold SUPN as of Q1 2020.

  • M&G Investment Management reported no remaining Supernus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • M&G Investment Management sold 90,855 Supernus Pharmaceuticals shares in Q1 2020, an estimated $2.18M.
  • M&G Investment Management first reported a position in Supernus Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • M&G Investment Management's Supernus Pharmaceuticals position peaked at $2.18M in Q4 2019.
  • 208 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2020.

Based on M&G Investment Management's 13F filing for Q1 2020, filed 9 Apr 2020.